Joanne van Ryn earned an MSc and PhD in the Dept. Medical Sciences at McMaster University in Hamilton, Ontario, Canada, where her graduate studies focused on examining antithrombotic and anticoagulant properties of heparin fractions and similar compounds. She continued post-doctoral work at Boehringer Ingelheim, where she is currently still employed. Starting in 2008, Dr. van Ryn transitioned into Dabigatran Global Scientific Support and joined the Dept. CardioMetabolic Disease Research. She is involved in collaborative efforts with many academic centers to further understand the role of thrombin inhibition in disease processes and is a member of international societies that include International Society of Thrombosis and Hemostasis (ISTH), American Society of Hematology (ASH) and American Heart Association (AHA).

In addition, she has played a key role in the research and development of idarucizumab, the specific reversal agent for dabigatran. Currently she has joined the Dept. of Cardiovascular Medicine at Boehringer as Senior Medical Advisor, focusing on Medical Education and Scientific Support for dabigatran and its specific reversal agent, idarucizumab.